stoxline Quote Chart Rank Option Currency Glossary
  
Biofrontera Inc. (BFRI)
0.824  -0.035 (-4.07%)    03-09 16:00
Open: 0.865
High: 0.865
Volume: 547,457
  
Pre. Close: 0.859
Low: 0.8015
Market Cap: 10(M)
Technical analysis
2026-03-09 4:11:01 PM
Short term     
Mid term     
Targets 6-month :  1.12 1-year :  1.3
Resists First :  0.95 Second :  1.12
Pivot price 0.88
Supports First :  0.76 Second :  0.65
MAs MA(5) :  0.86 MA(20) :  0.85
MA(100) :  0.87 MA(250) :  0.84
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  51.2 D(3) :  62.4
RSI RSI(14): 43.5
52-week High :  1.19 Low :  0.53
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BFRI ] has closed above bottom band by 6.9%. Bollinger Bands are 44.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.89 - 0.9 0.9 - 0.9
Low: 0.83 - 0.84 0.84 - 0.84
Close: 0.85 - 0.86 0.86 - 0.87
Company Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Headline News

Mon, 09 Mar 2026
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Yahoo Finance

Mon, 09 Mar 2026
Biofrontera reports positive Phase 2b Ameluz PDT results for moderate to severe acne - TradingView

Thu, 26 Feb 2026
Biofrontera (NASDAQ: BFRI) wins PTAB decision on Sun Pharma patent claims - Stock Titan

Thu, 26 Feb 2026
U.S. patent board backs Biofrontera in battle over Sun Pharma patent - Stock Titan

Tue, 17 Feb 2026
Biofrontera Inc (NASDAQ: BFRI) recently announced that the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities has been completed. - Bitget

Tue, 17 Feb 2026
Biofrontera Inc. Announces Database Lock of Phase 1 - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 0 (M)
Shares Float 12 (M)
Held by Insiders 8.17e+006 (%)
Held by Institutions 12.1 (%)
Shares Short 252 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.751e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -47.3 %
Operating Margin -89.9 %
Return on Assets (ttm) -65 %
Return on Equity (ttm) -1 %
Qtrly Rev. Growth 3.716e+007 %
Gross Profit (p.s.) -35.72
Sales Per Share 304.33
EBITDA (p.s.) 3.8e+007
Qtrly Earnings Growth -1.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -2.36
Stock Dividends
Dividend 0
Forward Dividend 436860
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android